This scoping review aims at systematically mapping reported Objective: prognostic factors for spontaneous immunosuppression (IS) free allograft tolerance (operational tolerance, OT) in non-viral hepatitis and non-autoimmune disease liver transplant (LT) recipients who are undergoing immunosuppression withdrawal (ISW). The results may inform the subsequent conduct of a systematic review with a more specific review question.
Introduction
Liver transplantation (LT) currently remains the only longterm treatment option for patients with end-stage liver failure. The success of LT was enabled by the introduction of effective pharmacological immunosuppressive strategies, which mostly target recipient T lymphocyte responses. The drugs that mediate immunosuppression (IS) in LT recipients exert their effects either by inhibiting intracellular T lymphocyte signalling or cellular proliferation. Calcineurin inhibitors (CNIs) 1 and mammalian target of rapamycin inhibitors (mTOR-I) 2 target the former, whereas corticosteroids 3 or antimetabolites like mycophenolate mofetil 4 or azathioprine 5 impair the latter. Moreover, biologic agents blocking the anti-interleukin 2 receptor on activated T lymphocytes (e.g., basiliximab 6 ) or inhibiting T lymphocyte costimulation (preliminary data in kidney transplantation: belatacept 7 ) have been developed more recently to reduce CNI exposure.
While providing effective protection against acute and chronic cellular rejection of the allograft, lifelong IS, particularly corticosteroids and CNIs, are known to cause significant side effects 8 . Common side effects include various malignancies, cardiovascular and metabolic diseases, renal toxicity, as well as susceptibility to infections 9-14 . These significant side effects account for chronic morbidity and impair quality of life of LT recipients. Therefore, efforts to minimise exposure to immunosuppressive drugs while preserving graft integrity are warranted.
Among all solid organ transplants (SOT), the transplanted liver exhibits unique immunoregulatory properties, which render liver allografts less dependent on IS [15] [16] [17] . The attributed mechanisms of liver allograft tolerance are complex and may include deficient antigen presentation, large antigen load, neutralisation of alloantibodies, regulatory T cell (Treg) generation, and long-term microchimerism [18] [19] [20] [21] [22] . Accordingly, LT recipients usually require less intensive IS treatment with lower levels and/or numbers of immunosuppressive drugs compared to other SOT recipients 23 . In addition, human leukocyte antigen (HLA) match requirements between donor and recipient are less stringent, and the incidence and severity of acute cellular rejection (ACR) episodes are lower and usually better tolerated in LT as compared to other SOT recipients 24 .
Based on these particular features, clinical studies that examined IS minimization or even complete IS withdrawal (ISW) in LT recipients have been initiated already in the 1990s 25-28 . Most of these ISW studies (at least all of the recent ones) applied predefined eligibility criteria such as absence of recent rejection episodes or absence of significant histological lesions in a baseline biopsy 29, 30 . In all studies, a significant subset of study participants exhibited stable allograft function and histological graft integrity despite complete ISW 31 . In agreement with the nomenclature used in the literature, we herein call this state of spontaneous immunological transplant tolerance operational tolerance (OT) 32 . However, the majority of study participants still would experience an ACR episode or develop abnormal liver function tests following ISW and eventually require the reinstitution of immunosuppressive drugs 31 (ISW failure). The mechanisms underlying ISW success or failure in LT recipients are currently not completely elucidated. Likewise, whether ISW outcomes may be predictable at all (see below) or IS minimisation is a safer alternative to complete ISW is not yet known 33 .
The discovery of OT has promoted extensive research activity over the last two decades 34 . On the one hand, it is important to explore the factors that are associated with or enable the development of OT in a subset of transplant recipients 35 . More detailed knowledge on such predictors of spontaneous OT will help to refine the eligibility criteria for LT recipients to participate in ISW trials and hopefully increase the fraction of successful ISW attempts. On the other hand, researchers have started to address the question as to whether OT can be induced by immune manipulation prior to ISW. Thus, infusion of donor-derived hematopoietic stem cells 36-40 , Treg 41 , regulatory dendritic cells (DCreg) 42 or mesenchymal stem cells 43,44 , as well as lymphodepletion protocols using T lymphocyte-directed antibodies 45 have been or are being tested for their potential to induce tolerance 31 .
Why it is important to do this review?
Regarding the therapeutic dilemma of deleterious effects of chronic IS vs. the risk of ISW failure and graft injury after LT, there is a medical need to define clinical and biochemical markers to predict the success of ISW. Up to now, there is only one systematic review that addressed the benefits and harms of ISW in LT recipients 46 . It focused on CNI and included only randomized controlled trials (RCTs) comparing ISW and IS continuation after LT. The authors identified a single ongoing RCT, which has been published in the meantime 47 . In this RCT, the non-inferiority analysis of ISW vs. unchanged IS maintenance treatment on a composite morbidity/mortality endpoint was inconclusive. Based on these results and an unpublished scoping search in the literature that did not identify any new RCTs on this comparison, we concluded that there was not enough data for a new systematic review approach comparing ISW and IS continuation after LT.
In contrast, the number of publications that highlight predisposing factors or biomarkers for spontaneous OT in ISW cohorts is increasing 35 . We, therefore, reasoned that the systematic scoping for evidence on such factors would best inform the community regarding the therapeutic dilemma of IS after LT. Accordingly, this scoping review will for the first time systematically collect biomarkers and clinical parameters that are likely predictors of spontaneous OT. The anticipated results shall set the basis for subsequent evidence syntheses or clinical trials with a sharpened research focus. Any evidence
Amendments from Version 1
In version 2, we aimed to clarify three issues: i) The scoping review will include paediatric and adult patients ii) The scoping review will focus on studies on full IS withdrawal and exclude studies on IS minimisation iii) The primary objective of the scoping review will be to map all published prognostic factors for spontaneous OT Any further responses from the reviewers can be found at the end of the article that will help understand the spontaneous development of OT and increase the fraction of successful ISW by enabling an informed preselection of ISW candidates is of great value to the community, as it will provide valuable guidance in the therapeutic dilemma of IS after LT.
Study aim and objectives/questions
The objective of this scoping review will be to map all published prognostic factors for spontaneous OT in non-viral hepatitis and non-autoimmune disease LT recipients who are undergoing ISW. The obtained results may inform the subsequent conduct of a systematic review with a more targeted review question.
Specifically, the review questions are: i) What are clinical parameters and biomarkers that predispose LT recipient ISW candidates to achieve spontaneous OT?
ii) What are the success rates of ISW and achievement of spontaneous OT in LT recipients?
iii) What are the rates of graft loss in LT recipients following ISW?
Protocol

Data collection Eligibility criteria Population, Intervention, Outcomes
The primary eligibility criterion will be the assessment of spontaneous OT, i.e. rejection-free liver allograft survival for at least one year following ISW. LT recipients of any age or stage will be included, but recipients with underlying autoimmune diseases, replicative viral disease and/or multi-organ recipients will be excluded. Studies reporting on mixed populations will be included, if less than 20% of the study population has a viral or autoimmune liver disease aetiology. Studies that do not report the liver disease aetiologies for LT in their population will also be included. All pharmacological IS regimens including combination treatments being completely withdrawn will be eligible. However, studies addressing dose reduction of IS including IS minimisation, withdrawal of a subset of drugs from IS combination treatments (e.g. withdrawal of corticosteroids in patients on CNI maintenance treatment), or conversion between IS regimens (e.g. CNI to mTOR-I conversion vs. CNI continuation) will be excluded.
We will include studies that assess an association of pre-ISW clinical parameters or biomarkers on the development of OT. Studies exclusively addressing the effectiveness of induction or immunomodulation therapies for development of OT (using lymphodepletion or infusion with regulatory immune cells) will be excluded. Prespecified pre-ISW clinical parameters potentially predicting OT are sex, recipient age at LT, time since LT, history of episodes of rejection, liver histology, pharmacologic IS regimen, living (LD) or deceased donor (DD) LT, degree of kinship (or HLA match) of the donor, lymphocytotoxic crossmatch, liver disease aetiology, and previous pregnancies, SOT, or blood transfusions. Prespecified pre-ISW biomarkers potentially predicting OT are any up-or downregulated immune cell subsets (detected by flow cytometry or mass cytometry), any up-or downregulated genes or micro RNAs in the liver allograft or peripheral blood (detected by gene microarray, quantitative PCR, or RNA-seq), epigenetic markers, and anti-HLA antibodies (detected by ELISA, single antigen bead assay, or complement-dependent cytotoxicity assay). Owing to the risk of confounding by interrupted IS in the OT cohort (i.e. featuring successful ISW), data on post-ISW biomarkers will be excluded unless the same biomarkers were measured in the same patients already before ISW.
Types of study to be included
We will include prospective, retrospective, randomised, and non-randomised studies irrespective of publication status and including case-control and cross-sectional designs. By reporting on those patients that did not achieve OT after ISW most relevant studies would include a "control cohort" by default. Principal investigators of ongoing studies and conference abstracts will be contacted twice by email for the sharing of their data. Conference abstracts where the data was subsequently published in a peer-reviewed article will be excluded. Animal studies, case reports, case series (i.e. publications where patient histories of exclusively tolerant or non-tolerant ISW-liver recipients are reported 48 ), reviews, letters, and editorials will be excluded. No language or publication date restrictions will be applied.
Identification of relevant literature. An information specialist (CA-H) will develop the search strategies, which will be reviewed by a second information specialist. Database-specific subject headings and text words (synonyms and word variations) for liver transplantation, ISW, and OT, graft survival, or liver biopsy will be used. We will search the electronic databases Embase via Elsevier, Medline via Ovid, and the Cochrane Central Register of Controlled Trials (CENTRAL). The search string for Embase is provided in Box 1. We will also search the study registry clinicaltrials.gov as well as the World Health Organization's International Clinical Trials Registry Platform (ICTRP) for ongoing studies. All retrieved references will be exported to EndNote X9 and deduplicated.
One reviewer (CA-H) will screen the deduplicated references based on their titles and abstracts. All potentially relevant references will be retrieved in full-text and independently assessed by two reviewers (CA-H, JV). Any disagreements over eligibility will be resolved by consensus. Where necessary, a third review author (SH) will make a final judgement. All judgements at the full-text screening stage will be collected in a standardised MS Excel 2016 form. Articles in foreign languages that none of the review authors is familiar with will be checked for eligibility by other researchers before translation will be considered. Potentially relevant ongoing studies and conference abstracts will only be included if principal investigators will provide us with chartable data that relate to our primary outcomes (see below).
To identify possible additional studies that will escape our electronic database searches, we will screen the bibliographic references and the citations of all included articles that are indexed in Scopus or the Web of Science.
Data analysis
Quality appraisal. Within the framework of this scoping review, no quality appraisal is planned. Data charting. Next to reported prognostic and non-prognostic factors (clinical parameters and biomarkers) for OT, which will be the primary outcomes, we will also chart the percentage of successful ISW and achievement of sustained OT and the rate of graft loss in each trial as the secondary outcomes. Two reviewers (CA-H, JV) will independently chart the data from each eligible article using a jointly developed MS Excel 2016 charting form that will be pilot tested using four eligible fulltext articles. If necessary, the charting form will be updated in an iterative process. Any disagreements will be solved by discussion. Data will be sought for the following variables:
• Article characteristics such as first author, year of publication, country of origin, and bibliographic details 
Strategy for data synthesis and presentation.
For each included article, ongoing study, or conference abstract with data, we will present the charted data in a "results of individual sources of evidence" table. For the synthesis of collated prognostic factors (biomarkers and clinical parameters) for OT, we will use descriptive statistics showing the individual sources of evidence that support each factor. In addition to a tabular view, the results will be narratively synthesized in the review text. Together, these results will provide a comprehensive scope of past research activity on this topic and likely identify promising future research avenues.
Design and reporting guidelines
This scoping review will be conducted along with the guidelines by the Joanna Briggs Institute 49 and reported according to the "Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews" (PRISMA-ScR) statement 50 .
Dissemination of results
The completed review will be published in a peer-reviewed journal.
Study status
Start date of search: July 2019; anticipated completion date of review: May 2020.
Current study status: preliminary searches, yes; piloting of the study selection process, yes; formal screening of search results against eligibility criteria, started; data extraction, no; data analysis, no.
Conclusions
Since the first reports of spontaneous OT in LT 25-28 , numerous studies of ISW have been published (reviewed in 32). These studies were initially uncontrolled and heterogeneous in their design, rendering any comparison between them and any conclusions difficult to draw. Following the creation of international consortia (Immune Tolerance Network -ITN -in the US and Reprogramming the Immune System for the Establishment of Tolerance -RISET -in Europe), inclusion/exclusion criteria of ISW studies in LT have been harmonised, thus allowing cross-comparisons and cross-validations between studies. For instance, two ongoing multicenter trials (LIFT 51 and OPTIMAL 52 ) share the same inclusion/exclusion criteria.
These ISW trials have in parallel fuelled the need to find reliable biomarkers for the identification of those patients who are more likely to successfully stop IS, a problem that is most critical for the safety and future applicability of ISW. While clinically not available yet, several biomarkers have already been evaluated in LT recipients. In this scoping review, we will map all information on this body of literature. In addition to that, our searches in clinical trial registries will provide an overview of the current research activity in the field. The anticipated results will allow us to determine possible research gaps and whether any future systematic reviewing and meta-analysis efforts are warranted.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Author Response 27 Jan 2020 , University of Basel, Basel, Switzerland Christian Appenzeller-Herzog Dear Prof. Kelly, Thank you very much for your constructive reviewer report and for drawing our attention to different issues in our protocol and possibilities for improvement. We are most happy with your judgements that this ambitious review has an obvious potential benefit to patients and that our protocol paper is of an acceptable scientific standard. With regard to your criticism, we would like to address the three points you raised: i) pediatric or adult patients?, ii) IS withdrawal and minimisation?, iii) difficulties to cope with review question 1:
Pediatric/adult: This review will include all ISW studies irrespective of LT recipient age. Our protocol already states in the subsection "population, intervention, outcomes" that "LT recipients of any age or stage will be included". To make this clearer to the reader we have now also added this information in the abstract, which now reads: "We will consider studies that record any clinical parameter or biomarker before the initiation of ISW in paediatric or non-viral hepatitis and non-autoimmune disease LT recipients …" adult The question whether or not OT-predicting factors differ in children and adults is interesting and important. Potentially, the planned systematic mapping of published predicting factors could provide some clues on this in the final review.
IS withdrawal/minimisation: This review will only focus on full ISW studies and exclude studies on IS minimisation. Our protocol already holds the following statement in the subsection "population, intervention, outcomes": "However, studies addressing dose reduction of IS, (…) will be excluded". To clarify that also IS minimization studies will be considered ineligible we have now implemented the following extension: "However, studies addressing dose reduction of IS , (…) will be excluded". including IS minimisation Review question 1: This is an important issue and we thank you for pointing this out. The objective of this scoping review is to collect and map all available evidence of OT-predicting factors. If no such factors can be identified, this result, albeit negative, will still be of importance and worth reporting. However, as you are pointing out, the formulations in our protocol are implying that our aim is to "identify" such factors in the literature. Instead, we should state that our objective is the mapping of all available evidence on such factors. In response to this important point of criticism, we have implemented the following revisions: Abstract: "This scoping review aims at systematically mapping reported prognostic factors for spontaneous immunosuppression (IS) free allograft tolerance (operational tolerance, OT) in non-viral hepatitis and non-autoimmune disease liver transplant (LT) recipients who are undergoing immunosuppression withdrawal (ISW)." Study aim and objectives/questions: "The objective of this scoping review will be to map all published prognostic factors for spontaneous OT in non-viral hepatitis and non-autoimmune disease LT recipients who are undergoing ISW."
We sincerely hope that these amendments to our protocol will help convince you to fully approve the revised version of our manuscript. Thank you again for your invaluable help in this matter.
